Citations, Scopus, n (citation density)
|
Citations, Web of Science, n (citation density)
|
Authors
|
Title
|
Year
|
1661 (110.7)
|
1510 (100.7)
|
Singh et al.
|
Preventing foot ulcers in patients with diabetes
|
2005
|
1297 (86.5)
|
1208 (80.5)
|
Boulton et al.
|
The global burden of diabetic foot disease
|
2005
|
1207 (80.5)
|
1171 (78.1)
|
Falanga
|
Wound healing and its impairment in the diabetic foot
|
2005
|
795 (99.4)
|
762 (95.3)
|
Lipsky et al.
|
2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections
|
2012
|
782 (37.2)
|
685 (62.3)
|
Ramsey et al.
|
Incidence, outcomes, and cost of foot ulcers in patients with diabetes
|
1999
|
758 (47.4)
|
637 (39.8)
|
Lipsky et al.
|
Diagnosis and treatment of diabetic foot infections
|
2004
|
720 (34.3)
|
628 (29.9)
|
Reiber et al.
|
Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings
|
1999
|
694 (31.5)
|
600 (27.3)
|
Armstrong et al.
|
Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation
|
1998
|
660 (36.7)
|
553 (30.7)
|
Abbott et al.
|
The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort
|
2002
|
655 (43.7)
|
576 (38.4)
|
Armstrong et al.
|
Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial
|
2005
|
588 (34.6)
|
546 (32.1)
|
Jeffcoate and Harding
|
Diabetic foot ulcers
|
2003
|
561 (21.6)
|
419 (16.1)
|
Caputo et al.
|
Assessment and management of foot disease in patients with diabetes
|
1994
|
544 (181.3)
|
524 (174.7)
|
Armstrong et al.
|
Diabetic foot ulcers and their recurrence
|
2017
|
520 (27.4)
|
487 (25.6)
|
Veves et al.
|
Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial
|
2001
|
518 (15.2)
|
369 (10.9)
|
Edmonds et al.
|
Improved survival of the diabetic foot: the role of a specialized foot clinic
|
1986
|
511 (23.2)
|
433 (16.7)
|
Wieman et al.
|
Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study
|
1998
|
511 (18.3)
|
417 (14.9)
|
Veves et al.
|
The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study
|
1992
|
497 (19.1)
|
421 (16.2)
|
Young et al.
|
The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study
|
1994
|
492 (41.0)
|
427 (35.6)
|
Boulton et al.
|
Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists
|
2008
|
483 (20.1)
|
401 (16.7)
|
Steed et al.
|
Effect of extensive debridement and treatment on the healing of diabetic foot ulcers
|
1996
|
481 (40.1)
|
455 (37.9)
|
Prompers et al.
|
Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study
|
2008
|
475 (33.9)
|
337 (24.1)
|
Frykberg et al.
|
Diabetic foot disorders. A clinical practice guideline (2006 revision)
|
2006
|
473 (18.9)
|
403 (16.1)
|
Steed et al.
|
Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers
|
1995
|
466
(27.4)
|
430
(25.3)
|
Marston et al.
|
The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial
|
2003
|
464 (22.1)
|
363 (17.3)
|
Boyko et al.
|
A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study
|
1999
|
460 (18.4)
|
339 (13.6)
|
Grayson et al.
|
Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients
|
1995
|
458 (35.2)
|
411 (31.6)
|
Prompers et al.
|
High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study
|
2007
|
442 (22.1)
|
382 (19.1)
|
Pham et al.
|
Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial
|
2000
|
442 (21.0)
|
124 (5.9)
|
American Diabetes Association
|
Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. American Diabetes Association
|
1999
|
406 (21.4)
|
329 (17.3)
|
Armstrong et al.
|
Off-loading the diabetic foot wound: a randomized clinical trial
|
2001
|
383 (27.4)
|
363 (25.9)
|
Lavery et al.
|
Risk factors for foot infections in individuals with diabetes
|
2006
|
360 (30.0)
|
347 (28.9)
|
Choi et al.
|
In vivo wound healing of diabetic ulcers using electrospun nanofibers immobilized with human epidermal growth factor (EGF)
|
2008
|
360 (20.0)
|
334 (18.6)
|
Lobmann et al.
|
Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients.
|
2002
|
352 (20.7)
|
311 (18.3)
|
Moulik et al.
|
Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology
|
2003
|
352 (16.0)
|
266 (12.1)
|
Reiber et al.
|
The burden of diabetic foot ulcers
|
1998
|
341 (12.6)
|
287 (10.6)
|
Apelqvist et al.
|
Long-term prognosis for diabetic patients with foot ulcers
|
1993
|
340 (17.9)
|
299 (15.7)
|
Oyibo et al.
|
A comparison of two diabetic foot ulcer classification systems: the Wagner and the University of Texas wound classification systems
|
2001
|
334 (19.6)
|
330 (19.4)
|
Sheehan et al.
|
Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial
|
2003
|
329 (13.2)
|
265 (10.6)
|
McNeely et al.
|
The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks?
|
1995
|
326 (13.6)
|
272 (11.3)
|
Gentzkow et al.
|
Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers
|
1996
|
322 (21.5)
|
284 (18.9)
|
Cavanagh et al.
|
Treatment for diabetic foot ulcers
|
2005
|
322 (15.3)
|
285 (13.6)
|
Smiell et al.
|
Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies
|
1999
|
319 (14.5)
|
251 (11.4)
|
Lavery et al.
|
Practical criteria for screening patients at high risk for diabetic foot ulceration
|
1998
|
318 (26.5)
|
325 (27.1)
|
Dowd et al.
|
Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP)
|
2008
|
316 (14.4)
|
239 (10.9)
|
Frykberg et al.
|
Role of neuropathy and high foot pressures in diabetic foot ulceration
|
1998
|
315 (22.5)
|
326 (23.3)
|
Blakytny and Jude
|
The molecular biology of chronic wounds and delayed healing in diabetes
|
2006
|
311 (14.1)
|
256 (11.6)
|
Abbott et al.
|
Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration
|
1998
|
310 (12.9)
|
246 (10.3)
|
Faglia et al.
|
Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study
|
1996
|
309 (14.0)
|
263 (12.0)
|
Mayfield et al.
|
Preventive foot care in people with diabetes
|
1998
|
307 (43.9)
|
311 (44.4)
|
Moura et al.
|
Recent advances on the development of wound dressings for diabetic foot ulcer treatment--a review
|
2013
|
306 (15.3)
|
264 (13.2)
|
Apelqvist and Larsson
|
What is the most effective way to reduce incidence of amputation in the diabetic foot?
|
2000
|
298 (14.2)
|
272 (13.0)
|
Margolis et al.
|
Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis
|
1999
|
283 (31.4)
|
279 (31.0)
|
Lu et al.
|
Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial
|
2011
|
263 (32.9)
|
269 (33.6)
|
Bakker et al.
|
Practical guidelines on the management and prevention of the diabetic foot 2011
|
2012
|
254 (15.9)
|
331 (20.7)
|
Boulton et al.
|
Neuropathic diabetic foot ulcers
|
2004
|
231 (19.2)
|
347 (28.9)
|
Blume et al.
|
Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial
|
2008
|